Considering the outstanding anti-tumor effect of silencing RanBP3 in both imatinib sensitive and resistant CML cells (Figures 2, 3), it is necessary to investigate the relationship between RanBP3 and imatinib sensitivity in these cells. This evidence concerns the gene RANBP3 and chronic myelogenous leukemia, BCR-ABL1 positive.